Medrad year-end revenues exceed last years
Medrad Inc. said it achieved sales revenues of $344 million in 2004, an increase of 17 percent over the previous year. Additional financial terms were not disclosed.
The Pittsburgh, Pa.-based company attributed the increase to a recent corporate reorganization in addition to a of number product successes, such as the Stellant CT Injection system, the 8-Channel Neurovascular Array Coil and Medrad's multi-vendor service (MVS) unit.
Medrad's January 2004 reorganization created three strategic business units: Computed Tomography (CT), Cardiovascular (CV), and Magnetic Resonance (MR). Each unit includes product development, marketing, regulatory and support teams, Medrad said.
The Pittsburgh, Pa.-based company attributed the increase to a recent corporate reorganization in addition to a of number product successes, such as the Stellant CT Injection system, the 8-Channel Neurovascular Array Coil and Medrad's multi-vendor service (MVS) unit.
Medrad's January 2004 reorganization created three strategic business units: Computed Tomography (CT), Cardiovascular (CV), and Magnetic Resonance (MR). Each unit includes product development, marketing, regulatory and support teams, Medrad said.